Scynexis (SCYX) Prepaid Assets (2013 - 2026)
Scynexis' (SCYX) quarterly Prepaid Assets came in at $1.5 million in Q2 2026, down 2.41% on a YoY basis from $1.6 million in Q2 2025, and up 67.57% quarter-over-quarter from $919000.0 in Q1 2026.
Analysis
Scynexis (SCYX) Prepaid Assets (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Prepaid Assets for 14 consecutive years, with $1.5 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Prepaid Assets fell 2.41% year-over-year to $1.5 million; the trailing twelve-month figure through Jun 2026 stood at $1.5 million (down 2.41% YoY), and the FY2025 full-year result was $263000.0, down 87.96% from the prior year.
- Prepaid Assets advanced to $1.5 million in Q2 2026 per SCYX's latest filing, from $919000.0 in the prior quarter.
- Across five years, Prepaid Assets topped out at $5.5 million in Q4 2023 and bottomed at $263000.0 in Q4 2025.
- Historically, Prepaid Assets has averaged $2.3 million across 5 years, with a median of $1.7 million in 2023.
- The sharpest annual moves came in 2023 and 2025: Prepaid Assets surged 121.65% in 2023, then plunged 87.96% in 2025.
- Over 5 years, Prepaid Assets stood at $2.5 million in 2022, then soared by 121.65% to $5.5 million in 2023, then plunged by 60.63% to $2.2 million in 2024, then slumped by 87.96% to $263000.0 in 2025, then surged by 485.55% to $1.5 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $1.5 million, $919000.0, and $263000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.54 Mn |
| Mar 31, 2026 | 919,000.00 |
| Dec 31, 2025 | 263,000.00 |
| Sep 30, 2025 | 686,000.00 |
| Jun 30, 2025 | 1.58 Mn |
| Mar 31, 2025 | 1.45 Mn |
| Dec 31, 2024 | 2.18 Mn |
| Sep 30, 2024 | 1.54 Mn |
| Jun 30, 2024 | 1.42 Mn |
| Mar 31, 2024 | 1.58 Mn |
| Dec 31, 2023 | 5.55 Mn |
| Sep 30, 2023 | 3.17 Mn |
| Jun 30, 2023 | 2.67 Mn |
| Mar 31, 2023 | 1.73 Mn |
| Dec 31, 2022 | 2.50 Mn |
| Sep 30, 2022 | 4.14 Mn |
| Jun 30, 2022 | 4.15 Mn |
| Mar 31, 2022 | 3.92 Mn |
| Dec 31, 2021 | 3.57 Mn |
| Sep 30, 2021 | 3.16 Mn |